K Health CAIHL draft report

K Health: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

K Health’s current enterprise offering includes dynamic intake, PatientGPT record questions, and clinician care. Patient questioning and institutional routing are distinct functions. The old direct consumer service is historical, and partner-specific privacy and refusal controls remain unverified.

Scope and agency posture

Health-system enterprise intake, PatientGPT record conversation and virtual care. The discontinued direct consumer service is historical context.

Posture: Mixed, institution-led.

Axis: 46/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The current homepage markets EHR-integrated dynamic intake and PatientGPT, alongside board-certified physician primary care. Its partner quotations describe both patient questions and institutional guidance along a care pathway. https://khealth.com/

• The linked HIPAA notice returned 403 in the single targeted governance follow-up. No fresh privacy or amendment terms were recovered. https://khealth.com/hipaa-notice

Patient authority

Inference from the documented workflow: PatientGPT offers direct questioning of records, while intake and care routing remain institutionally configured. These should not be collapsed into a single clinician-only function.

Critical capacity

Editorial assessment: Record conversation may help patients understand history and prepare questions. The marketing does not establish source citations, correction of extracted context or alternatives to AI intake.

Informed control

Editorial assessment: Enterprise branding confirms the current deployment model. It does not verify notice within each partner app, sponsor reporting or the consequences of refusal.

Assessment and limits

Mixed, institution-led remains reasonable, but the new assessment must acknowledge patient-facing record inquiry and distinguish it from intake and clinical decision support.

Confidence: Low to moderate, product claims with blocked governance follow-up.

Remaining uncertainty: Partner-specific refusal, records correction, provenance and data-use controls remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-12. Historical assessment. Earlier claims are not automatically reverified by this publication.